Under new Food and Drug Administration (FDA) guidance on "low risk" wearable technology and software, AI-powered health tools are rapidly expanding, leading to major implications for cost, access, and consumer autonomy in health care.
One of the clearest examples is Doctronic, an AI-powered platform for prescription refills that rolled out in Utah this month. The FDA has not moved to regulate or stop Doctronic from operating, largely because the FDA does not regulate the actual practice of medicine. That leaves Doctronic free to innovate to patients' benefit—prescription refills with Doctronic are currently $4 and could fall as the company grows.
